D
Tempest Therapeutics, Inc. TPST
$3.03 -$0.03-0.82% NASDAQ
Recommendation
Prev Close
$3.05
Volume
16
Avg Vol (90D)
97,187
Market Cap
$15.03M
Dividend & Yield
--
52-Week Range
$3.01 - $13.65
P/E (TTM)
--
EPS (TTM)
-$10.40
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
11/26/2025 - Globe Newswire
Tempest Therapeutics Secures $4.25M in Direct Offering
11/26/2025 - TipRanks Financial Blog
Tempest Therapeutics (TPST) Announces $4.25M Direct Offering
11/25/2025 - GuruFocus
Tempest Therapeutics announces $8.35M registered direct offering, concurrent private placement
11/25/2025 - SeekingAlpha.com: All News
Tempest Therapeutics announces $8.35M registered direct offering, concurrent private placement
11/25/2025 - Seeking Alpha - Healthcare
Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering
11/25/2025 - The Fly
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
11/25/2025 - Globe Newswire
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
11/19/2025 - Benzinga
Tempest Therapeutics (TPST) Expands Pipeline with Strategic Acquisition
11/19/2025 - GuruFocus
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
11/19/2025 - Globe Newswire
tempest turns factor lifeline trading majority stake car ts and ceo
11/19/2025 - FierceBiotech.com - Biotech
Critical Contrast: Tempest Therapeutics (NASDAQ:TPST) versus Vaxart (NASDAQ:VXRT)
11/6/2025 - Ticker Report
Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year
11/5/2025 - The Fly
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
11/5/2025 - Globe Newswire
Tempest Therapeutics' Promising Phase 3 Trial for Liver Cancer Treatment
10/27/2025 - TipRanks Financial Blog
Tempest Therapeutics Inc Reports Q2 2025 EPS of -$2.07, Beating Estimates; Net Loss at $7.9 Million
8/13/2025 - GuruFocus
Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)
8/11/2025 - The Fly
Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58
8/11/2025 - SeekingAlpha.com: All News
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
8/11/2025 - Globe Newswire
Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment
8/4/2025 - TipRanks Financial Blog
Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial
6/30/2025 - The Fly
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
6/30/2025 - Globe Newswire
Tempest Therapeutics Secures $4.1M in Direct Offering
6/12/2025 - TipRanks Financial Blog
After Major Oncology Conference, All Eyes Turn to Industry Innovation
6/12/2025 - PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$36.17M
EBIT (TTM)
-$36.42M
Net Income (TTM)
-$36.05M
Balance Sheet
Total Assets (Q)
$17.13M
Total Debt (Q)
$8.41M
Total Liabilities (Q)
$10.78M
Book Value Per Share (Q)
$1.43
Cash Flow
Cash from Operations (TTM)
-$33.40M
Cash from Investing (TTM)
-$3.00K
Cash from Financing (TTM)
$18.44M
Net Change in Cash (TTM)
-$14.95M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
1.77
7-Day Total Return
-17.80%
30-Day Total Return
-71.27%
60-Day Total Return
-72.12%
90-Day Total Return
-61.02%
Year to Date Total Return
-72.89%
1-Year Total Return
-75.54%
2-Year Total Return
-93.12%
3-Year Total Return
-86.23%
5-Year Total Return
--
52-week Low
Nov 25, 2025 - $3.01
52-week High
Jan 06, 2025 - $13.65
Valuation
Market Cap
$15.03M - Nano Cap
Enterprise Value
$15.92M
Price/Sales (TTM)
--
Price/Book (Q)
2.13
Dividends and Shares
Shares Outstanding
4.44
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tempesttx.com
Phone Number
415 798 8589
Address
2000 Sierra Point Parkway
Brisbane, CA 94005
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed